News

French healthcare company Sanofi has received separate regulatory approvals from the European Commission (EC) for two of its enzyme replacement therapies to treat rare diseases. The European regulator approved Nexviadyme (avalglucosidase alfa) to treat the full spectrum of both infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). French healthcare company Sanofi has received separate regulatory approvals from the European Commission (EC) for two of its enzyme replacement therapies to treat rare diseases. The European regulator approved Nexviadyme (avalglucosidase alfa) to treat the full spectrum of both infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD).